Mark Hilton is "the consummate patent litigator", say sources, who note that he "consistently comes up with innovative solutions". One source comments: “He has all the skills and never bends under pressure – which must make him a nightmare opponent to face!”
Mark is one of the team's prominent litigators, with particular experience advising on complex multi-jurisdictional IP disputes.
Mark is co-head of Bird & Bird’s international life sciences and healthcare group, and a partner in the international intellectual property group. He is based in London.
As co-head of the international life sciences and healthcare group, Mark specialises in patent litigation and advice in the area of pharmaceuticals, biosimilars, biotechnology (including in food) and medical devices. However, his interests and experience also extend to a diverse range of technical fields, in particular the food and beverage and financial services sectors.
In recent years, he has been particularly involved in the coordination and running of various pan-European patent actions across several jurisdictions. Recent reported UK IP trials in which he has been involved include Actavis v Eli Lilly (the landmark case of recent years that introduced, for the first time, a doctrine of equivalents into English law); Smith & Nephew v ConvaTec (successfully defending the validity of a key patent protecting an advanced wound dressing); and Actavis v Boehringer Ingelheim (reference to the CJEU on a matter of SPC law). He also coordinates the trademark enforcement work for one of the major high street banks and has regularly advised international food companies in relation to regulatory, patent and trademark matters.
Mark has a BSc in chemistry and a PhD in organic chemistry which he obtained while working in the industry before undertaking training with Bird & Bird. He has written and spoken on a range of IP topics, is an associate of the Chartered Institute of Patent Attorneys (CIPA) and a member of the Law Society of Ireland.